HIV treatment has advanced significantly, with modern antiretroviral medicines helping many people achieve and maintain viral suppression. One of the newer treatments is Sunlenca (lenacapavir), a long-acting HIV medicine designed for certain adults with multidrug-resistant HIV-1. Sunlenca is different from many traditional HIV medicines because it is administered by subcutaneous injection every six months after an initial loading regimen. However, it is not a stand-alone cure for HIV and is not intended for everyone living with HIV. In the United States, Sunlenca is approved for heavily treatment-experienced adults with multidrug-resistant HIV-1 whose
Sunlenca is the brand name for lenacapavir, an HIV-1 capsid inhibitor.
Unlike several older antiretroviral drug classes that target specific viral enzymes, lenacapavir targets the HIV capsid, a protein structure surrounding the virus's genetic material. Its activity affects multiple stages of the HIV life cycle.
The FDA approved Sunlenca in December 2022 for a specific population of adults with multidrug-resistant HIV-1. It must be used in combination with other antiretroviral medicines that make up an effective treatment regimen.
Sunlenca is not generally an initial HIV treatment.
The U.S. indication covers adults who:
A healthcare professional determines whether the existing HIV regimen is failing and whether Sunlenca can be incorporated into an effective combination.
This means a person newly diagnosed with HIV or someone whose HIV is already well controlled on a standard regimen would not normally receive Sunlenca simply because it is a newer or longer-acting medicine.
Lenacapavir works by targeting the HIV capsid.
The capsid is an important structural component of HIV. It helps protect the virus's genetic material and plays roles during several stages of viral replication.
By interfering with capsid function, lenacapavir can inhibit HIV at multiple points in its life cycle.
This mechanism is different from medicines such as:
Because Sunlenca has a different mechanism, it can be particularly valuable when HIV has developed resistance to multiple other antiretroviral classes.
Sunlenca treatment begins with an oral loading regimen and injections.
The FDA-approved prescribing information provides two initiation approaches. One approach includes two 300-mg tablets on Day 1 and two tablets on Day 2, followed by the injectable dose. Another approach uses oral doses on Days 1, 2, and 8, followed by the injection on Day 15.
After initiation, the maintenance dose consists of:
927 mg administered by subcutaneous injection every 6 months, with a ±2-week dosing window.
The injections are administered under the skin in the abdominal area by a healthcare professional.
Traditional HIV treatment commonly involves daily oral medication.
Sunlenca introduces a substantially different dosing schedule for people who meet its specific indication.
Instead of receiving the injectable medicine every few weeks or months, the maintenance dose is administered twice each year.
This can reduce the frequency of injection visits while providing long-lasting exposure to lenacapavir.
However, the six-month dosing schedule does not mean that HIV treatment only needs to be considered twice a year. The other antiretroviral medicines in the treatment regimen may need to be taken on a different schedule.
One of the most important points about Sunlenca is that it is not intended to function as monotherapy for the approved treatment indication.
It is prescribed in combination with other antiretroviral medicines.
The other medicines are selected according to the person's HIV treatment history, resistance profile, tolerability, interactions, and other clinical factors.
Using lenacapavir without an adequate companion regimen could increase the risk of virologic failure and resistance.
Treatment-experienced HIV refers to HIV in a person who has previously received antiretroviral therapy.
Over time, HIV can develop resistance to some medicines, particularly when treatment is interrupted, medication exposure is inadequate, or the virus acquires resistance mutations.
People who have received multiple treatment regimens may eventually have fewer effective medicines remaining.
For this population, a medicine with a new mechanism of action can provide an important additional treatment component.
Multidrug-resistant HIV is HIV that has developed resistance to multiple antiretroviral medicines or drug classes.
Resistance can make treatment considerably more complicated.
Healthcare professionals may review:
The objective is to construct a regimen containing enough active medicines to achieve durable viral suppression.
The primary objective of HIV treatment is to suppress HIV replication.
The FDA's clinical-trial summary reports that, after 52 weeks of Sunlenca treatment combined with other antiretroviral medicines, 83% of participants achieved HIV-1 RNA suppression in the study population evaluated.
Clinical-trial results do not guarantee that an individual patient will experience the same outcome.
Treatment response depends on factors such as the virus's resistance profile, the activity of companion medicines, adherence, tolerability, and overall health.
Resistance management is particularly important with long-acting HIV medicines.
Because lenacapavir can remain in the body for an extended period, missing scheduled injections or failing to maintain the accompanying antiretroviral regimen can result in declining drug concentrations.
The prescribing information warns that inadequate adherence can lead to loss of virologic response and development of resistance. Residual lenacapavir concentrations may remain in systemic circulation for 12 months or longer after administration.
For this reason, scheduled follow-up is an important part of treatment.
Sunlenca is designed around a six-month dosing schedule.
Missing a scheduled injection should not be treated as an ordinary missed daily pill.
Because of the medicine's long half-life and the potential for resistance when drug levels decline, the prescribing information provides specific management instructions for missed doses.
A healthcare professional should determine the appropriate next step rather than simply waiting for the next routine appointment.
Sunlenca can interact with certain medicines.
The FDA prescribing information specifically lists strong CYP3A inducers as contraindicated with Sunlenca.
Medication reviews should therefore include:
A healthcare professional or pharmacist can determine whether a particular medication is compatible with lenacapavir.
Like other medicines, Sunlenca can cause side effects.
Injection-site reactions are an important consideration because the medicine is administered subcutaneously.
Possible injection-site reactions can include:
The prescribing information also contains warnings concerning immune reconstitution syndrome and prolonged residual drug concentrations.
A healthcare professional can explain expected reactions and identify symptoms that require medical attention.
One notable characteristic of long-acting lenacapavir treatment is the possibility of injection-site nodules.
These are localized areas of firmness under the skin.
Because the medicine is designed to remain in the body for an extended period, the injection site can behave differently from a short-acting injection.
Patients should discuss persistent, painful, inflamed, or otherwise concerning injection-site changes with the healthcare team.
Sunlenca is one part of a much larger HIV treatment landscape.
Other treatment approaches include:
Integrase strand transfer inhibitors prevent HIV from inserting its genetic material into the DNA of infected cells.
They are widely used in modern HIV treatment and are included in many first-line treatment combinations.
Nucleoside or nucleotide reverse transcriptase inhibitors are commonly combined with other antiretroviral classes.
Examples of medicines in this category include tenofovir, emtricitabine, lamivudine, and abacavir.
Protease inhibitors interfere with HIV protease, an enzyme required for producing mature infectious virus particles.
They remain important for certain treatment situations, including some cases involving drug resistance.
Long-acting injectable HIV treatment is another approach that can reduce daily pill requirements for appropriately selected patients.
Cabotegravir and rilpivirine are examples of long-acting antiretroviral medicines used in certain treatment settings.
The eligibility requirements and dosing schedules differ from Sunlenca.
Daily oral ART remains a major component of HIV care.
Modern combination regimens can suppress HIV effectively and are often simpler than older treatment combinations.
A healthcare professional may select a daily regimen based on:
For many people, a daily oral regimen remains an effective and convenient approach.
HIV treatment is individualized.
Important factors can include:
For treatment-experienced individuals with multidrug-resistant HIV, resistance testing and historical treatment information can be especially important.
Lenacapavir has also been studied for HIV prevention, but this should not be confused with the current U.S. Sunlenca treatment indication.
Sunlenca is approved in the United States for treatment of certain heavily treatment-experienced adults with multidrug-resistant HIV.
The prevention use of lenacapavir involves a different product indication and dosing strategy.
This distinction is important because HIV treatment and HIV prevention have different goals and clinical requirements.
| Feature | Sunlenca-Based Treatment | Daily Oral ART |
|---|---|---|
| Main use | Certain multidrug-resistant HIV cases | Broad range of HIV treatment situations |
| Dosing | Injection every 6 months after initiation | Usually daily |
| Oral loading | Required during initiation | Depends on regimen |
| Used alone? | No | Depends on complete regimen |
| Resistance considerations | Particularly important | Important |
| Appropriate for everyone with HIV? | No | Treatment is individualized |
Sunlenca should therefore not be viewed simply as a more convenient replacement for every HIV medication.